Brokerage firm Scotiabank Upgrades its rating on Concordia Healthcare Corp(NASDAQ:CXRX). The shares have been rated Sector Perform. Previously, the analysts had a Underperform rating on the shares. The rating by Scotiabank was issued on Sep 19, 2016.
In a different note, On Aug 15, 2016, CIBC said it Downgrades its rating on Concordia Healthcare Corp. The shares have been rated ‘Underperformer’ by the firm. On Aug 15, 2016, GMP Securities said it Downgrades its rating on Concordia Healthcare Corp. The shares have been rated ‘Hold’ by the firm. On Aug 15, 2016, Goldman Sachs said it Maintains its rating on Concordia Healthcare Corp. In the research note, the firm Lowers the price-target to $26.00 per share. The shares have been rated ‘Neutral’ by the firm. On Aug 4, 2016, TD Securities said it Downgrades its rating on Concordia Healthcare Corp. The shares have been rated ‘Hold’ by the firm.
Concordia Healthcare Corp(CXRX) last announced its earnings results on Aug 12, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $231.71M. Analysts had an estimated revenue of $234.58M. Earnings per share were $1.38. Analysts had estimated an EPS of $1.45.
Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.